JVIM 2020

Question 1

Retrospective evaluation of the use of the international myleoma working group response criteria in dogs with secretory multiple myeloma
Author: Moore et al

Answer 1

MST longer for dogs with >90% denistometric M-protein reduction. Detection of progressive disease correlated with clinical signs - should be used for monitoring dogs with MM.
Response criteria categorized by serum globulins or radial immunodiffusion was not correlated with OST or clinical findings.

Question 2

What is a treatment option for dogs with obstructive hydrocephalus caused by tumours affecting the third ventricle?

Answer 2

Palliative ventricyloperitoneal shunting.

Question 3

Name your two main differentials for tumours affecting the third ventricle?

Answer 3

Ependymoma or choroid plexus tumours (most common, comprising 7% all primary tumours of CNS tumours in dogs

Question 4

What are the main complications associated with ventriculoperitoneal shunting?

Answer 4

Occlusion of the device, increased pressure in the contralateral ventricle.

Question 5

What was MST for dogs with tumour in the third ventricle treated only with ventriculoperitoneal shunting?

Answer 5

14 months ( only 4 dogs included)

Question 6

How many dogs treated with toceranib for ASAC had a registered clinical benefit?

Answer 6

70%, 20% had PR, 50% had SD

Question 7

What was the PFS and OST for dogs with ASAC treated with toceranib +/- surgery or chemo by Heaton et al? and what was the toceranib associated PFS and OST?

Answer 7

300 days and 830 days respectively. 300 and 430 days

Question 8

What is the mechanism of action of rabacfosadine?

Answer 8

Nucleotide analog (prodrug); it is taken up by lymphoid cells, metabolised to 9-(2.phosphonylmethoxyethyl guanine) which inhibit DNA synthesis and repair after being doubly phosphorylated

Question 9

Is L-asp and rabacfosadine considered a safe and efficacious treatment option for relapsed multicentric LSA?

Answer 9

Yes

Question 10

What is the MPFS for dogs rescued with RAB and L-asp?

Answer 10

2 months (63 days) for all, 140 days if CR is achieved.

Question 11

What is the overall response rate for RAB and L.asp as rescue?

Answer 11

67% . 40% CR

Question 12

Name the two negative prognostic factors for MPFS in dogs rescued with RAB and L-asp?

Answer 12

Previous administration of l-asp and lack of CR

Question 13

What was the most common complications with FNA of adrenal lesions?

Answer 13

haemorrhage

Question 14

What is the reported death rate associated with sampling of adrenal lesions?

Answer 14

1%

Question 15

Which factors were associated with greater odds of relapse in dogs treated surgically for insulinoma?

Answer 15

Stage and post-op hypoglycaemia

Question 16

What was the MST for dogs with insulinoma treated surgically?

Answer 16

372 days

Question 17

Which factor was associated with better outcome in dogs with insulinoma?

Answer 17

Transient hyper-glycemic

Question 18

How many dogs developed diabetes mellitus post-of after sx treatment for insulinoma?

Answer 18

20%

Question 19

Is cardiac troponin correlated to cardiac toxicity caused by doxo?

Answer 19

An increase in troponin I has been documented after serial doxo, but optimal timing for measuring in is unknown.

Question 20

microRNA has show potential as a biomarker for toxicity associated with which chemotherapeutic drug?

Answer 20

Doxorubicin

Question 21

Which alterations were found in dogs treated with toceranib as adjuvant treatment for surgically resected carcinomas?

Answer 21

Reduced number of T-regs and HIF1alpha positive cells. Lower VEGFR2.

Question 22

Does adjuvant toceranib improve TTP in dogs with carcinoma?

Answer 22

TTP increased from 300 to 360 days

Question 23

Which microRNA may have value biomarkers for diagnosis and prognosis?

Answer 23

mi19b and mi18a